Ceva Bussan Animal Health Now Operational – Inside Japan’s Landmark 2026 Animal Health Merger

In the most significant foreign animal health corporate action in Japan this year, France-based Ceva Santé Animale (Ceva) and Japanese global trading giant Mitsui & Co., Ltd. (Mitsui) have officially finalized a definitive joint venture agreement, establishing Ceva Bussan Animal Health.

The blockbuster restructuring involves Mitsui transferring a 60% controlling shareholding of its wholly owned subsidiary, Bussan Animal Health (BAH), over to Ceva. The newly unified corporate vehicle will be operated by Ceva as the controlling shareholder, backed by a simultaneous, substantial secondary equity investment by Mitsui directly into Ceva’s global parent organization.

The move establishes a consolidated, full-line animal health platform engineered to dramatically reshape distribution, therapeutic delivery, and veterinary market access across Japan.

Operational Synergy: Heritage Meets Global Pipeline

The creation of Ceva Bussan Animal Health is structured specifically to resolve historical operational fragmentation in the Japanese domestic veterinary channel by creating a direct bridge between localized distribution networks and international research pipelines.

• The Local Heritage: Bussan Animal Health brings a distinguished 75-year domestic operational history, an established corporate brand, and a deep-tier nationwide technical sales force that maintains direct commercial relationships with livestock operations and companion animal clinics across every prefecture

• The Global Tech Iniection: Ceva—the world’s fifth-largest animal health company by sales—injects its vast international portfolio of advanced swine, ruminant, and poultry biologicals, along with its fast-growing, high-margin companion animal Over-The-Counter (OTC) behavior and wellness lines

• Executive Leadership Alignment: To ensure seamless integration, Tadahiro Ohashi (former Managing Director of Ceva Japan) has been tapped as Chief Executive Officer of the joint venture, working alongside Akito Umeda (former CEO of BAH), who will serve as Deputy CEO

Macro Swine Headwind: Spanish ASF Restraints Alter Portfolio Planning

While the joint venture provides an optimized platform for long-term growth, its immediate swine biological and pharmaceutical division is navigating complex, highly fluid macroeconomic trade disruptions.

Japanese Blanket Ban

Japan’s Ministry of Agriculture, Forestry, and Fisheries (MAFF) continues to maintain strict blanket import suspensions on Spanish pork following the late-2025 African Swine Fever (ASF) wildlife outbreaks detected near Barcelona. Prior to the quarantine, Spain was Japan’s leading non-EU pork supplier, holding an estimated 10% import market share valued at over €648 million annually.

Portfolio Pivot

This ongoing trade restriction acts as a major strategic variable for Ceva Bussan’s newly integrated swine portfolio. Because local Japanese hog producers are moving aggressively to ramp up domestic production to fill the supply deficit left by missing Spanish imports, demand for advanced farmgate biosecurity, immune-boosting therapies, and preventive swine vaccines has sharply spiked.

While the ban restricts certain international pork trade lines, Ceva Bussan is leveraging this shift to push its proprietary domestic herd health management systems, positioning itself as a vital partner for Japanese farms scaling up under tight biosecurity parameters.

Financial and Market Context

The strategic logic of the joint venture is supported by robust baseline figures. In fiscal year 2025, Bussan Animal Health generated €40 million ($43.4 million) in standalone revenues.

By consolidating teams, eliminating redundant warehousing, and streamlining commercial workflows within a single legal corporate structure, management expects the joint venture to capture immediate distribution efficiencies. The integration allows the entity to maximize profits in Japan’s premium-grade animal health market while creating an export vehicle to push domestically developed animal health intellectual property (IP) out to global markets through Mitsui’s international trading networks.

Executive Perspectives

“With Ceva Bussan Animal Health, we are opening a transformative new chapter for animal health in Japan,” stated Marc Prikazsky, Executive Chairman of Ceva Animal Health. “By combining the deep local roots and 75-year expertise of BAH with Ceva’s global innovation capabilities, we are creating a company uniquely positioned to better serve veterinarians, farmers, and pet owners alike.”

Representatives from Mitsui & Co. commented: “This enhanced joint venture represents a cornerstone of our reinforced collaboration with Ceva. By uniting our broad portfolio of business assets—including animal nutrition—with Ceva’s world-class biological expertise, we aim to contribute significantly to the sustainable, secure development of the Japanese and global animal health industries.”